Virus-like particle vaccine (VLP vaccine)

The entry 'N/A – prophylactic VLP vaccine' does not refer to a specific biological target molecule, such as a receptor or enzyme, but rather describes a vaccine modality or delivery platform. Virus-Like Particles (VLPs) are multiprotein structures that mimic the organization and conformation of authentic native viruses but lack the viral genome, rendering them non-infectious and non-replicative (Source: NIH, 2023). They function by presenting viral antigens in a highly repetitive, symmetric manner that is efficiently recognized by the immune system, thereby inducing robust humoral and cellular immune responses (Source: PubMed, 2021). Common examples of this technology include vaccines for Human Papillomavirus (HPV) and Hepatitis B Virus (HBV) (Source: Nature Reviews Immunology, 2018). Because this entry represents a drug class or prophylactic intervention rather than a molecular target, it is classified as an incorrect target designation for drug-target interaction mapping.

Other names

VLPVirus-like particleProphylactic VLP vaccine

VLPs mimic the structure of authentic viruses to stimulate B-cell and T-cell mediated immune responses without the risk of viral replication.